vs
MESA LABORATORIES INC（MLAB）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
RE/MAX Holdings, Inc.的季度营收约是MESA LABORATORIES INC的1.1倍（$71.1M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs 2.0%，领先3.5%），MESA LABORATORIES INC同比增速更快（3.6% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $18.0M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -4.7%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
MLAB vs RMAX — 直观对比
营收规模更大
RMAX
是对方的1.1倍
$65.1M
营收增速更快
MLAB
高出5.5%
-1.8%
净利率更高
MLAB
高出3.5%
2.0%
自由现金流更多
RMAX
多$15.5M
$18.0M
两年增速更快
MLAB
近两年复合增速
-4.7%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $71.1M |
| 净利润 | $3.6M | $1.4M |
| 毛利率 | 64.2% | — |
| 营业利润率 | 12.2% | 13.1% |
| 净利率 | 5.6% | 2.0% |
| 营收同比 | 3.6% | -1.8% |
| 净利润同比 | 316.6% | -75.2% |
| 每股收益（稀释后） | $0.65 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABRMAX
| Q4 25 | $65.1M | $71.1M | ||
| Q3 25 | $60.7M | $73.2M | ||
| Q2 25 | $59.5M | $72.8M | ||
| Q1 25 | $62.1M | $74.5M | ||
| Q4 24 | $62.8M | $72.5M | ||
| Q3 24 | $57.8M | $78.5M | ||
| Q2 24 | $58.2M | $78.5M | ||
| Q1 24 | $58.9M | $78.3M |
净利润MLABRMAX
| Q4 25 | $3.6M | $1.4M | ||
| Q3 25 | $2.5M | $4.0M | ||
| Q2 25 | $4.7M | $4.7M | ||
| Q1 25 | $-7.1M | $-2.0M | ||
| Q4 24 | $-1.7M | $5.8M | ||
| Q3 24 | $3.4M | $966.0K | ||
| Q2 24 | $3.4M | $3.7M | ||
| Q1 24 | $-254.6M | $-3.4M |
毛利率MLABRMAX
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
营业利润率MLABRMAX
| Q4 25 | 12.2% | 13.1% | ||
| Q3 25 | 7.8% | 25.0% | ||
| Q2 25 | 5.1% | 19.3% | ||
| Q1 25 | 2.4% | 7.2% | ||
| Q4 24 | 9.2% | 5.9% | ||
| Q3 24 | 6.1% | 19.4% | ||
| Q2 24 | 9.6% | 20.6% | ||
| Q1 24 | -460.6% | 5.8% |
净利率MLABRMAX
| Q4 25 | 5.6% | 2.0% | ||
| Q3 25 | 4.1% | 5.4% | ||
| Q2 25 | 8.0% | 6.4% | ||
| Q1 25 | -11.4% | -2.6% | ||
| Q4 24 | -2.7% | 8.0% | ||
| Q3 24 | 5.9% | 1.2% | ||
| Q2 24 | 5.8% | 4.7% | ||
| Q1 24 | -432.2% | -4.3% |
每股收益（稀释后）MLABRMAX
| Q4 25 | $0.65 | — | ||
| Q3 25 | $0.45 | — | ||
| Q2 25 | $0.85 | — | ||
| Q1 25 | $-1.30 | — | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | $0.63 | — | ||
| Q2 24 | $0.62 | — | ||
| Q1 24 | $-47.26 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $118.7M |
| 总债务越低越好 | $68.4M | $432.2M |
| 股东权益账面价值 | $186.7M | $452.4M |
| 总资产 | $434.8M | $582.5M |
| 负债/权益比越低杠杆越低 | 0.37× | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资MLABRMAX
| Q4 25 | $29.0M | $118.7M | ||
| Q3 25 | $20.4M | $107.5M | ||
| Q2 25 | $21.3M | $94.3M | ||
| Q1 25 | $27.3M | $89.1M | ||
| Q4 24 | $27.3M | $96.6M | ||
| Q3 24 | $24.3M | $83.8M | ||
| Q2 24 | $28.5M | $66.1M | ||
| Q1 24 | $28.2M | $82.1M |
总债务MLABRMAX
| Q4 25 | $68.4M | $432.2M | ||
| Q3 25 | $69.4M | $433.3M | ||
| Q2 25 | $70.3M | $434.4M | ||
| Q1 25 | $71.3M | $435.3M | ||
| Q4 24 | $72.2M | $436.2M | ||
| Q3 24 | $73.1M | $437.2M | ||
| Q2 24 | $74.1M | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益MLABRMAX
| Q4 25 | $186.7M | $452.4M | ||
| Q3 25 | $178.5M | $448.1M | ||
| Q2 25 | $172.5M | $442.4M | ||
| Q1 25 | $159.8M | $433.5M | ||
| Q4 24 | $155.2M | $429.5M | ||
| Q3 24 | $161.5M | $423.1M | ||
| Q2 24 | $150.7M | $418.4M | ||
| Q1 24 | $145.4M | $412.0M |
总资产MLABRMAX
| Q4 25 | $434.8M | $582.5M | ||
| Q3 25 | $430.4M | $582.2M | ||
| Q2 25 | $435.7M | $574.8M | ||
| Q1 25 | $433.3M | $571.4M | ||
| Q4 24 | $433.3M | $581.6M | ||
| Q3 24 | $454.1M | $578.6M | ||
| Q2 24 | $440.4M | $571.4M | ||
| Q1 24 | $446.8M | $566.7M |
负债/权益比MLABRMAX
| Q4 25 | 0.37× | 0.96× | ||
| Q3 25 | 0.39× | 0.97× | ||
| Q2 25 | 0.41× | 0.98× | ||
| Q1 25 | 0.45× | 1.00× | ||
| Q4 24 | 0.47× | 1.02× | ||
| Q3 24 | 0.45× | 1.03× | ||
| Q2 24 | 0.49× | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $33.5M |
| 自由现金流率自由现金流/营收 | 27.7% | 47.1% |
| 资本支出强度资本支出/营收 | 1.1% | 10.4% |
| 现金转化率经营现金流/净利润 | 5.17× | 28.39× |
| 过去12个月自由现金流最近4个季度 | $37.9M | $56.8M |
8季度趋势，按日历期对齐
经营现金流MLABRMAX
| Q4 25 | $18.8M | $40.9M | ||
| Q3 25 | $8.2M | $17.7M | ||
| Q2 25 | $1.9M | $4.6M | ||
| Q1 25 | $12.7M | $5.7M | ||
| Q4 24 | $18.1M | $59.7M | ||
| Q3 24 | $5.3M | $17.6M | ||
| Q2 24 | $10.7M | $15.9M | ||
| Q1 24 | $12.9M | $9.4M |
自由现金流MLABRMAX
| Q4 25 | $18.0M | $33.5M | ||
| Q3 25 | $7.1M | $16.4M | ||
| Q2 25 | $884.0K | $2.9M | ||
| Q1 25 | $11.9M | $4.0M | ||
| Q4 24 | $17.3M | $53.0M | ||
| Q3 24 | $3.5M | $16.3M | ||
| Q2 24 | $9.9M | $14.0M | ||
| Q1 24 | $12.3M | $6.8M |
自由现金流率MLABRMAX
| Q4 25 | 27.7% | 47.1% | ||
| Q3 25 | 11.7% | 22.4% | ||
| Q2 25 | 1.5% | 4.0% | ||
| Q1 25 | 19.2% | 5.3% | ||
| Q4 24 | 27.6% | 73.2% | ||
| Q3 24 | 6.0% | 20.8% | ||
| Q2 24 | 16.9% | 17.8% | ||
| Q1 24 | 21.0% | 8.6% |
资本支出强度MLABRMAX
| Q4 25 | 1.1% | 10.4% | ||
| Q3 25 | 1.8% | 1.8% | ||
| Q2 25 | 1.7% | 2.2% | ||
| Q1 25 | 1.2% | 2.3% | ||
| Q4 24 | 1.3% | 9.1% | ||
| Q3 24 | 3.1% | 1.7% | ||
| Q2 24 | 1.5% | 2.4% | ||
| Q1 24 | 0.9% | 3.3% |
现金转化率MLABRMAX
| Q4 25 | 5.17× | 28.39× | ||
| Q3 25 | 3.32× | 4.45× | ||
| Q2 25 | 0.40× | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | 1.54× | 18.22× | ||
| Q2 24 | 3.17× | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
